<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04317300</url>
  </required_header>
  <id_info>
    <org_study_id>19-011437</org_study_id>
    <nct_id>NCT04317300</nct_id>
  </id_info>
  <brief_title>Feasibility of Treatment for Vaping Cessation</brief_title>
  <acronym>VAPEscape</acronym>
  <official_title>The Feasibility of Treatment for Vaping Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are gathering information on the feasibility of treating e-cigarette users with&#xD;
      12-weeks of varenicline (Chantix®) in assisting with stopping the use of e-cigarettes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Because the process of developing nicotine dependence and the reinforcing mechanisms of&#xD;
      nicotine delivered in high concentrations are similar between tobacco cigarettes and newer&#xD;
      generation electronic cigarettes, the investigators hypothesize that evidence based treatment&#xD;
      approaches used in treating tobacco dependence should be effective in treating dependence on&#xD;
      electronic cigarettes. Since there is no existing evidence base for treatment of electronic&#xD;
      cigarette dependence, preliminary evidence is needed from feasibility and open label studies&#xD;
      to guide in the development of future randomized clinical trials. In this study, vaping&#xD;
      participants will be treated with a 12 week course of varenicline as well as have nicotine&#xD;
      dependence counseling through a certified tobacco treatment specialist followed up 12 weeks&#xD;
      post end of medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2022</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>12 weeks of varenicline</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of e-cigarette abstinence after 12 weeks of treatment with varenicline plus brief behavioral therapy as an aid to stop vaping</measure>
    <time_frame>12 weeks</time_frame>
    <description>The rate of self reported e-cigarette abstinence verified biochemically with nicotine and nicotine metabolites in urine will be assessed at the end of a 12-week course of varenicline plus brief behavioral therapy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Vaping</condition>
  <arm_group>
    <arm_group_label>E-cigarette users</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who are regular users of e-cigarettes will be treated with a 12 week course of varenicline for stopping vaping.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Varenicline</intervention_name>
    <description>Dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 11 weeks of treatment.</description>
    <arm_group_label>E-cigarette users</arm_group_label>
    <other_name>Chantix®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>brief behavioral therapy</intervention_name>
    <description>brief behavioral therapy</description>
    <arm_group_label>E-cigarette users</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥18 years and ≤65 years of age;&#xD;
&#xD;
          -  No use of tobacco in any form (except E-cigarettes) in the past 3 months;&#xD;
&#xD;
          -  currently using e-cigarettes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current moderate or severe depression&#xD;
&#xD;
          -  Use of any treatments for tobacco dependence within the past 30 days;&#xD;
&#xD;
          -  Recent history (past 3 months) of abuse of, or dependence on, a substance other than&#xD;
             nicotine;&#xD;
&#xD;
          -  Women who are pregnant or lactating, or who are of childbearing potential and are&#xD;
             likely to become pregnant during the medication phase, or a male who is able to father&#xD;
             a child, and are not willing to use a reliable form of contraception,&#xD;
&#xD;
          -  Subject describes having a medical history of: a) unstable angina; b) myocardial&#xD;
             infarction within the past 3 months; c) coronary angioplasty; or d) an untreated&#xD;
             cardiac dysrhythmia;&#xD;
&#xD;
          -  Subject currently has cancer [excluding non-melanoma skin cancer] not in remission;&#xD;
&#xD;
          -  Known allergy to varenicline;&#xD;
&#xD;
          -  Subject has a medical condition deemed by the investigators to be exclusionary to the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Taylor T Hays, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shawn C Fokken, CCRP</last_name>
    <phone>(507) 293-2740</phone>
    <email>GIMRESEARCHSTUDIES@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ivana Croghan, PhD</last_name>
    <phone>(507) 293-2740</phone>
    <email>GIMRESEARCHSTUDIES@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 14, 2020</study_first_submitted>
  <study_first_submitted_qc>March 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2020</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>J. Taylor Hays</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>electronic cigarettes</keyword>
  <keyword>vaping</keyword>
  <keyword>e-cigarettes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varenicline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

